AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23485014 — intervention group
Group type: EXPERIMENTAL
Intervention: Real high‐frequency rTMS (10 Hz, 100% resting motor threshold, 5‐sec on, 10‐sec off for 15 min; 3000 pulses)
Number of subjects: 16
Study 23485014 — intervention group
Group type: EXPERIMENTAL
Intervention: Real high‐frequency rTMS
Number of subjects: 16
Study 23485014 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS (eSham)
Number of subjects: 16
Study 21624752 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily montelukast 4 mg
Number of subjects: 1771
Study 21624752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent montelukast 4 mg
Number of subjects: 1771
Study 21624752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1771
Study 19537367 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream applied to one side of the scalp and/or face for 12 weeks
Number of subjects: 9
Study 19537367 — intervention group
Group type: COMPARATOR
Intervention: Ultrabase cream (placebo) applied to the other side for 12 weeks
Number of subjects: 9
Study 16423001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg, amoxicillin 1 g, levofloxacin 500 mg, all given twice daily for 7 days (LAL)
Number of subjects: 106
Study 16423001 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily, metronidazole 400 mg thrice daily, bismuth subcitrate 120 mg and tetracycline 500 mg four times daily for 7 days (quadruple)
Number of subjects: 106
Study 16423001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, amoxicillin plus levofloxacin (LAL)
Number of subjects: 106
Study 16423001 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy
Number of subjects: 106
Study 15229013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 600 microg 1x, 400 microg every 4 hours 5x
Number of subjects: 126
Study 15229013 — intervention group
Group type: COMPARATOR
Intervention: Concentrated intravenous oxytocin plus low-dose vaginal PGE(2) 10 mg every 6 hours 4x
Number of subjects: 126
Study 11300576 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant anxious attachment
Number of subjects: 241
Study 11300576 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant avoidant attachment
Number of subjects: 241
Study 11300576 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant avoidant attachment with confederate avoidant attachment
Number of subjects: 241
Study 9237050 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotoxicity Scale (patient-based report scale)
Number of subjects: 189
Study 8431124 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 5% povidone‐iodine enemas and 24‐hour intravenous cefotaxime sodium and metronidazole hydrochloride (Group 1)
Number of subjects: 341
Study 8431124 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injections of ceftriaxone sodium (1 g) and ornidazole (1 g) and two 5% povidone‐iodine enemas (Group 2)
Number of subjects: 341
Study 8431124 — intervention group
Group type: COMPARATOR
Intervention: Saline enemas and 24‐hour intravenous cefotaxime sodium and metronidazole hydrochloride (Group 3)
Number of subjects: 341
Study 8431124 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 5% povidone‐iodine enemas (Group 1)
Number of subjects: 341
Study 8431124 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injections of ceftriaxone sodium (1 g) and ornidazole (1 g) (Group 2)
Number of subjects: 341
Study 8431124 — intervention group
Group type: COMPARATOR
Intervention: Saline enemas (Group 3)
Number of subjects: 341
Study 2887112 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms, four times daily for four weeks)
Number of subjects: 225
Study 2887112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 2887112 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 225
Study 30407682 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change program and health education
Number of subjects: 100
Study 30407682 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 100
Study 28035669 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE pre-oxygenation
Number of subjects: 40
Study 28035669 — intervention group
Group type: COMPARATOR
Intervention: Facemask pre-oxygenation
Number of subjects: 40
Study 25145323 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircraft noise exposure (60 events during one night, mean sound pressure level 46.9 ± 2.0 dB(A))
Number of subjects: 60
Study 25145323 — intervention group
Group type: COMPARATOR
Intervention: No noise condition (mean sound pressure level 39.2 ± 3.1 dB(A))
Number of subjects: 60
Study 23610100 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan 9 g/day
Number of subjects: 642
Study 23610100 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan 12/15 g/day (pooled)
Number of subjects: 642
Study 23610100 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan 3 g/day
Number of subjects: 642
Study 23610100 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan 6 g/day
Number of subjects: 642
Study 23610100 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan (various doses)
Number of subjects: 642
Study 23610100 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan
Number of subjects: 642
Study 23610100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 21886361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (maximum of 2 hours of sleep)
Number of subjects: 55
Study 19128767 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking-placebo
Number of subjects: 150
Study 19128767 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking-24% sucrose
Number of subjects: 150
Study 19128767 — intervention group
Group type: COMPARATOR
Intervention: No specific analgesic intervention (control group)
Number of subjects: 150
Study 16579697 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap with enamel matrix derivative (EMD)
Number of subjects: 22
Study 16579697 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap alone
Number of subjects: 22
Study 12723458 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release formulation of Fampridine (10 mg) in patients with spinal cord injury (n = 11)
Number of subjects: 17
Study 12723458 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 6) receiving oral doses of 10, 15, 20, and 25 mg of Fampridine
Number of subjects: 17
Study 10677406 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 10
Study 10677406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress
Number of subjects: 10
Study 9043560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 4% cream (30-minute application)
Number of subjects: 66
Study 9043560 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine-prilocaine cream (60-minute application)
Number of subjects: 66
Study 7942580 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/d)
Number of subjects: 50
Study 7942580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3218448 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term diazepam prophylaxis (n = 152)
Number of subjects: 289
Study 3218448 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (n = 137)
Number of subjects: 289
Study 3218448 — intervention group
Group type: EXPERIMENTAL
Intervention: Young age at onset
Number of subjects: 289
Study 29385840 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Assisted Intervention (VRAI) using Nintendo Wii Fit Plus
Number of subjects: 20
Study 29385840 — intervention group
Group type: COMPARATOR
Intervention: Traditional Rehabilitation Intervention (TRI) with theraband exercises
Number of subjects: 20
Study 28495562 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor with no predicted-active NRTIs
Number of subjects: 1277
Study 28495562 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor and raltegravir
Number of subjects: 1277
Study 28495562 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor monotherapy
Number of subjects: 1277
Study 28495562 — intervention group
Group type: EXPERIMENTAL
Intervention: One predicted-active NRTI
Number of subjects: 1277
Study 28495562 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or three active NRTIs
Number of subjects: 1277
Study 24946155 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling referral among average-risk group
Number of subjects: 2524
Study 24946155 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling referral among elevated-risk group
Number of subjects: 2524
Study 24946155 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling referral among high-risk group
Number of subjects: 2524
Study 24946155 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA testing among average-risk group
Number of subjects: 2524
Study 24946155 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA testing among elevated-risk group
Number of subjects: 2524
Study 24946155 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA testing among high-risk group
Number of subjects: 2524
Study 24946155 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived ovarian cancer risk
Number of subjects: 2524
Study 24946155 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of family history with a doctor
Number of subjects: 2524
Study 24946155 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that family history influenced risk
Number of subjects: 2524
Study 23349733 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (510 mg/day)
Number of subjects: 28
Study 23349733 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 28
Study 23349733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21944072 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-legged hold exercise on a round foam roll (unstable surface)
Number of subjects: 19
Study 21944072 — intervention group
Group type: COMPARATOR
Intervention: Single-legged hold exercise on the floor (stable surface)
Number of subjects: 19
Study 17615174 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-squat exercise (closed kinetic chain)
Number of subjects: 32
Study 17615174 — intervention group
Group type: COMPARATOR
Intervention: Straight leg raise exercise (open kinetic chain)
Number of subjects: 32
Study 16199491 — intervention group
Group type: EXPERIMENTAL
Intervention: In-school mediated communication campaign combined with community-based media effort
Number of subjects: 4216
Study 16199491 — intervention group
Group type: COMPARATOR
Intervention: Control communities (no intervention)
Number of subjects: 4216
Study 12858328 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meal test (CRMT)
Number of subjects: 7
Study 14698699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 115
Study 14698699 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (carbamazepine, phenytoin, or valproate)
Number of subjects: 115
Study 14698699 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 115
Study 10674506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermic CPB (32 degrees C)
Number of subjects: 20
Study 10674506 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB (>35 degrees C)
Number of subjects: 20
Study 8888299 — intervention group
Group type: EXPERIMENTAL
Intervention: Background grating with a spatial frequency of about 4 cycles deg‐1 (experiment 1)
Number of subjects: 0
Study 8888299 — intervention group
Group type: EXPERIMENTAL
Intervention: Background grating with a duty cycle of 50% (experiment 3)
Number of subjects: 0
Study 8888299 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of the background grating (experiment 2)
Number of subjects: 0
Study 1499145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low workload exercise (50% VO2max, 60 min, 3 times a week for 10 weeks)
Number of subjects: 26
Study 1499145 — intervention group
Group type: EXPERIMENTAL
Intervention: High workload exercise (75% VO2max, 60 min, 3 times a week for 10 weeks)
Number of subjects: 26
Study 1499145 — intervention group
Group type: EXPERIMENTAL
Intervention: High workload exercise
Number of subjects: 26
Study 1499145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low workload exercise
Number of subjects: 26
Study 6091505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytologic examination of induced sputum in addition to annual chest radiographic screening.
Number of subjects: 10387
Study 6091505 — intervention group
Group type: COMPARATOR
Intervention: Annual chest radiographic screening (control group).
Number of subjects: 10387
Study 3698521 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 14
Study 3698521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg daily
Number of subjects: 14
Study 3698521 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily + Nifedipine 30 mg daily
Number of subjects: 14
Study 31489188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemna minor (20 g of protein)
Number of subjects: 12
Study 31489188 — intervention group
Group type: COMPARATOR
Intervention: Green peas (20 g of protein)
Number of subjects: 12
Study 31489188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemna minor and Green peas
Number of subjects: 12
Study 27506727 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ‐16‐containing deodorant (DEO1)
Number of subjects: 0
Study 27506727 — intervention group
Group type: COMPARATOR
Intervention: Commercially available deodorant (DEO2)
Number of subjects: 0
Study 27506727 — intervention group
Group type: COMPARATOR
Intervention: Aluminium chlorohydrate-containing deodorant (DEO3)
Number of subjects: 0
Study 24965759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine test (LC) group
Number of subjects: 92
Study 24965759 — intervention group
Group type: COMPARATOR
Intervention: Glenohumeral (GH) group
Number of subjects: 92
Study 24965759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LC and GH)
Number of subjects: 92
Study 23669062 — intervention group
Group type: EXPERIMENTAL
Intervention: AM (Amlodipine) 10 mg/day + OM (Olmesartan Medoxomil) 40 mg/day
Number of subjects: 157
Study 23669062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 23669062 — intervention group
Group type: COMPARATOR
Intervention: AM (Amlodipine) 10 mg/day
Number of subjects: 157
Study 23669062 — intervention group
Group type: COMPARATOR
Intervention: OM (Olmesartan Medoxomil) 40 mg/day
Number of subjects: 157
Study 21515838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 or 100 mg daily) in the diet-alone group
Number of subjects: 2539
Study 21515838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 or 100 mg daily) in the insulin group
Number of subjects: 2539
Study 21515838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 or 100 mg daily) in the OHA group
Number of subjects: 2539
Study 21515838 — intervention group
Group type: COMPARATOR
Intervention: No aspirin in the insulin group
Number of subjects: 2539
Study 21515838 — intervention group
Group type: COMPARATOR
Intervention: No aspirin in the OHA group
Number of subjects: 2539
Study 21515838 — intervention group
Group type: COMPARATOR
Intervention: No aspirin in the diet-alone group
Number of subjects: 2539
Study 19484213 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis Home Programme (CHP)
Number of subjects: 33
Study 17038073 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care with access to a depression care manager and Problem Solving Treatment for 12 months
Number of subjects: 1801
Study 17038073 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 1801
Study 15537736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hippocampal lesions
Number of subjects: 0
Study 15537736 — intervention group
Group type: EXPERIMENTAL
Intervention: Rats with hippocampal lesions
Number of subjects: 0
Study 11558482 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 325
Study 11558482 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 325
Study 11558482 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Atorvastatin vs Simvastatin
Number of subjects: 325
Study 9070968 — intervention group
Group type: EXPERIMENTAL
Intervention: BMIPP
Number of subjects: 28
Study 9070968 — intervention group
Group type: COMPARATOR
Intervention: Thallium-201
Number of subjects: 28
Study 8387973 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 50 mg three times a day
Number of subjects: 39
Study 8387973 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 39
Study 2892451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 27
Study 2892451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 27
Study 2892451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 27
Study 2892451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2892451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 27
Study 2892451 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 27
Study 28472453 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Joule laser energy
Number of subjects: 26
Study 28472453 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-Joule laser energy
Number of subjects: 26
Study 28472453 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study 28502038 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered Intermediary interviews
Number of subjects: 270
Study 28502038 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Labels interviews
Number of subjects: 270
Study 28502038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sketch Reinstatement of Context interviews
Number of subjects: 270
Study 28502038 — intervention group
Group type: COMPARATOR
Intervention: Best-Practice police interview
Number of subjects: 270
Study 25562115 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) program, 6-week, six-lesson
Number of subjects: 762
Study 25562115 — intervention group
Group type: COMPARATOR
Intervention: Usual preventive mental health service for the first 6 months
Number of subjects: 762
Study 23745303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine hydrochloride 20 mL mixed with morphine 3 mg
Number of subjects: 158
Study 23745303 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 158
Study 20873998 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) treatment
Number of subjects: 84
Study 20873998 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid treatment
Number of subjects: 84
Study 20873998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RF and topical steroid treatment
Number of subjects: 84
Study 18276928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax (tooth‐borne) palatal expander
Number of subjects: 39
Study 18276928 — intervention group
Group type: COMPARATOR
Intervention: Acrylic‐bonded (tooth‐tissue borne) palatal expander
Number of subjects: 39
Study 17063298 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrojejunostomy (LGJ)
Number of subjects: 24
Study 17063298 — intervention group
Group type: COMPARATOR
Intervention: Open gastrojejunostomy (OGJ)
Number of subjects: 24
Study 14639566 — intervention group
Group type: COMPARATOR
Intervention: 150g added weight (placebo)
Number of subjects: 10
Study 14639566 — intervention group
Group type: EXPERIMENTAL
Intervention: 770g added weight
Number of subjects: 10
Study 14639566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1625g added weight
Number of subjects: 10
Study 14639566 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject preference for 770g added weight
Number of subjects: 10
Study 14639566 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject preference for 150g added weight
Number of subjects: 10
Study 14639566 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject preference for 1625g added weight
Number of subjects: 10
Study 10791374 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment guided by plasma N‐BNP concentration (BNP group)
Number of subjects: 69
Study 10791374 — intervention group
Group type: COMPARATOR
Intervention: Standardised clinical assessment (clinical group)
Number of subjects: 69
Study 10791374 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP group
Number of subjects: 69
Study 10791374 — intervention group
Group type: COMPARATOR
Intervention: Clinical group
Number of subjects: 69
Study 9290239 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiregional composite RR/LL
Number of subjects: 0
Study 9290239 — intervention group
Group type: EXPERIMENTAL
Intervention: Left facial composite (LL)
Number of subjects: 0
Study 9290239 — intervention group
Group type: EXPERIMENTAL
Intervention: Right facial composite (RR)
Number of subjects: 0
Study 9290239 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiregional composite LL/RR
Number of subjects: 0
Study 9290239 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal orientation (RL)
Number of subjects: 0
Study 9290239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror reversed (LR)
Number of subjects: 0
Study 8369005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release diltiazem (180 mg)
Number of subjects: 5
Study 8369005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release diltiazem (240 mg)
Number of subjects: 5
Study 8369005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release diltiazem (300 mg)
Number of subjects: 5
Study 8369005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release diltiazem (360 mg)
Number of subjects: 5
Study 8369005 — intervention group
Group type: COMPARATOR
Intervention: Immediate release diltiazem (60 mg, thrice a day)
Number of subjects: 5
Study 3484423 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 58